ClinicalTrials.gg
RecruitingNCT07285460ATLAS-KIDSUpdated Oct 27, 2026

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

A Phase 3 interventional study of Fitusiran and Clotting factor concentrates (CFC) or bypassing agents (BPA) in Hemophilia, sponsored by Sanofi. Recruiting at 37 sites in 12 countries. Open to male participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 27, 2026No longer in Romania13 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
1 Year to 11 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.

Planned enrollment
4th of 10
85 · median 70
Started
2025
the only one that year
Phase 3
6 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
4 of 10
Sanofi

Among the 10 studies testing fitusiran in Hemophilia A, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 3, and was the 10th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fitusiran

fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 1 Year to 11 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing fitusiran in Hemophilia A, or all of them as a file.
02

Study summary

This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to \<12 years) who have severe hemophilia A or B, with or without inhibitory antibodies to FVIII or FIX.

Number of participants:

Approximately 85 participants will be enrolled into the study:

  • Approximately 60 fitusiran-naïve participants with severe hemophilia A or B, with or without inhibitors (fitusiran-naïve arm), and
  • Approximately 25 participants with severe hemophilia A or B with inhibitors rolling over from the EFC15467* dose confirmation study (roll-over arm).

    • Fitusiran has been investigated in the pediatric population in study EFC15467, which enrolled male participants aged 1 to \<12 years with hemophilia A or B with inhibitors to examine the safety and tolerability of fitusiran in the pediatric population.

Participants will be enrolled into 1 of 2 arms:

  • Fitusiran-naïve: these participants have not previously received fitusiran, and they will undergo screening and study eligibility assessments. Once enrolled, they will go through a 24-week standard of care (SOC) period before starting fitusiran prophylaxis.
  • Roll-over participants from the EFC15467 study: only participants who are still on active treatment in study EFC15467 and consenting to study EFC17905 will be eligible to roll over. They will not need to undergo screening or further eligibility assessments. They will directly enroll into the fitusiran treatment period and continue treatment on their current fitusiran dose.

The duration of fitusiran treatment will be up to 160 weeks for the fitusiran-naïve arm and up to 60 weeks for the roll-over arm.

Read the detailed description

The duration of fitusiran treatment will be up to 160 weeks for the fitusiran-naïve arm and up to 60 weeks for the roll-over arm.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants not previously exposed to fitusiran are eligible to be included in the study only if all of the following criteria apply:

  • Participant must be 1 to \<12 years of age at the time of enrollment.
  • Participants must have severe hemophilia A or B (FVIII \<1% or FIX ≤2%) as evidenced by a central laboratory measurement at screening or documented medical record evidence.
  • Participants must meet inhibitor or non-inhibitor status as defined below:

Inhibitor:

Requiring use of BPA for prophylaxis or BPA as on-demand therapy for any bleeding episodes for at least the last 3 months prior to screening, and meet one of the following Nijmegen-modified Bethesda assay results criteria:

  • Inhibitor titer of ≥0.6 BU/mL at screening, OR
  • Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of 2 consecutive titers ≥0.6 BU/mL, OR
  • Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of 1 inhibitor titer ≥0.6 BU/mL and a history of anamnestic response, or severe allergic reaction (eg, anaphylaxis) or nephrotic syndrome

Non-inhibitor:

Requiring use of clotting factor concentrates (CFCs) for prophylaxis or CFCs as on-demand therapy for any bleeding episodes for at least the last 3 months prior to screening, and meet each of the following criterion:

  • Nijmegen-modified Bethesda assay inhibitor titer of \<0.6 BU/mL at screening, AND
  • No use of BPA to treat bleeding episodes for at least the last 3 months prior to screening

    • Participants must have adequate peripheral venous access, as determined by the Investigator, to allow the blood draws required by the study protocol.
    • Male: There are no requirements for this study except where required by local regulations.
    • Capable of giving signed /assent. A signed written informed consent must be obtained from parent(s)/legal guardian (hereafter referred to as the "parent"), as well as a written or oral assent obtained from participant, per local and national requirements.

Exclusion criteria

Exclusion Criteria:

Participants not previously exposed to fitusiran are excluded from the study if any of the following criteria apply:

  • Known co-existing bleeding disorders other than hemophilia A or B.
  • Presence of liver disease.
  • History of antiphospholipid antibody syndrome.
  • History of arterial or venous thromboembolism, unrelated to an indwelling venous access
  • Any condition (eg, medical concern), which in the opinion of the Investigator, would make the participant unsuitable for dosing or which could interfere with the study compliance, the participant's safety and/or the participant's participation in the completion of the treatment period of the study.
  • History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc.
  • Subjects with a central or peripheral indwelling catheter, with a history of venous access complications (such as infections, thrombosis) leading to hospitalization and/or systemic anticoagulation therapy in the last 12 months.
  • At screening, anticipated need of surgery during the study or planned surgery scheduled to occur during the study.
  • Completion of a surgical procedure within 14 days prior to screening, or currently receiving additional BPA infusion for postoperative hemostasis.
  • History of intolerance to SC injection(s).
  • Current participation in ITI therapy.
  • The use of emicizumab (Hemlibra®) or any non-factor bleed management treatment within 6 months prior to screening
  • Prior gene therapy
  • Current or future participation in another clinical study, scheduled to occur during this study, involving an product other than fitusiran or an investigational device.
  • AT activity \<60% at screening, as determined by central laboratory analysis.
  • Co-existing thrombophilic disorder.
  • Presence of an active virus infection
  • Presence of acute hepatitis A or Hepatitis E virus infection.
  • Presence of acute or chronic virus infection.
  • count ≤100 000/μL.
  • Presence of acute infection at screening.
  • (HIV) positive with a of \<400 cells/μL.
  • Estimated ≤45 mL/min/1.73 m2 (using the Schwartz formula).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Fitusiran-naïve arm

    Participants will go through a 24-week standard of care (SOC) period before receiving a selected dose of fitusiran at regular interval. If a fitusiran dose adjustment is needed during the study, participants will follow a specific dosing regimen as per study protocol.

    Drug: Fitusiran · Biological: Clotting factor concentrates (CFC) or bypassing agents (BPA) · Biological: Antithrombin concentrate (ATIIIC)

  • Experimental
    EFC15647 roll-over arm

    Participants will continue receiving their current fitusiran dose from EFC15467. If a fitusiran dose adjustment is needed during the study, participants will follow a specific dosing regimen as per study protocol.

    Drug: Fitusiran · Biological: Clotting factor concentrates (CFC) or bypassing agents (BPA) · Biological: Antithrombin concentrate (ATIIIC)

Interventions

  • Pharmaceutical form: solution for injection in PBS Route of administration: subcutaneous

    Also known as: SAR439774, Qfitlia™

  • BiologicalClotting factor concentrates (CFC) or bypassing agents (BPA)

    Pharmaceutical form: solution for injection Route of administration: intravenous injection

  • BiologicalAntithrombin concentrate (ATIIIC)

    Pharmaceutical form: solution for injection Route of administration: intravenous injection

06

What researchers measure

Primary outcomes

  1. Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs

    Time frame: Day 85 to Day 421 (fitusiran primary efficacy period); Day -168 to Day -1 (SOC period)

Secondary outcomes

  1. Annualized spontaneous bleeding rate (AsBR) in the fitusiran primary efficacy period and in the SOC period

    A spontaneous bleeding episode is a bleeding event that occurs for no apparent or known reason, particularly into the joints, muscles, and soft tissues

    Time frame: Day 85 to Day 421 (fitusiran primary efficacy period); Day -168 to Day -1 (SOC period)

  2. Annualized joint bleeding rate (AjBR) in the fitusiran primary efficacy period and in the SOC period

    A joint bleeding episode is characterized by an unusual sensation in the joint ("aura") in combination with 1) increasing swelling or warmth over the skin over the joint, 2) increasing pain, or 3) progressive loss of range of motion or difficulty in using the limb as compared with baseline

    Time frame: Day 85 to Day 421 (fitusiran primary efficacy period); Day -168 to Day -1 (SOC period)

  3. ABR in the fitusiran treatment period (160 weeks) for fitusiran-naïve participants

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs

    Time frame: Day 1 to Day 1121

  4. ABR in the fitusiran treatment period (60 weeks) for rolled-over participants

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs

    Time frame: Day 1 to Day 421

  5. Change in physical activity

    Change in physical activity as measured via the PROMIS questionnaire

    Time frame: From Day 1 to Day 421; From Week -24 to Day -1

  6. Change in pain intensity

    Change in pain intensity as measured via the PROMIS questionnaire

    Time frame: From Day 1 to Day 421; From Week -24 to Day -1

  7. Change in HRQoL

    Change in HRQoL as measured by the EuroQoL 5-dimension questionnaire

    Time frame: From Day 1 to Day 421; From Week -24 to Day -1

  8. Incidence, severity, seriousness, and relatedness of adverse events (AEs)

    All AEs are collected from the signing of the informed consent form (ICF) until last AT follow up visit

    Time frame: Date of signed ICF (Day -228 to Day -169) until last AT follow-up visit (Day 1121 + approximately 24 weeks)

  9. Change in total score and domain scores

    Change in total score and domain scores is assessed by the Hemophilia Joint Health Score

    Time frame: From Day 1 to Day 421; From Week -24 to Day -1

  10. Target joints resolution

    Target joints resolution assessed per ISTH criteria

    Time frame: At Day 421

07

Study locations

37 of 37 sites recruiting
  • The Luskin Orthopaedic Institute for Children- Site Number : 8400013
    Los Angeles, California 90007, United States
    Recruiting
  • Children's Hospital Los Angeles- Site Number : 8400002
    Los Angeles, California 90027, United States
    Recruiting
  • The Center for Inherited Blood Disorders- Site Number : 8400009
    Orange, California 92868, United States
    Recruiting
    • Suzette David · Contact714-221-1224
    • Vanessa Salinas · Principal investigator
  • UCLA Medical Center - Harbor- Site Number : 8400011
    Torrance, California 90509, United States
    Recruiting
  • University of Michigan Health System - Ann Arbor- Site Number : 8400003
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Cure 4 The Kids Foundation- Site Number : 8400001
    Las Vegas, Nevada 89147, United States
    Recruiting
  • Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400008
    Hackensack, New Jersey 07601, United States
    Recruiting
  • University of Texas - Southwestern Medical Center- Site Number : 8400015
    Dallas, Texas 75390, United States
    Recruiting
  • Investigational Site Number : 0560002
    Brussels, 1020, Belgium
    Recruiting
  • Investigational Site Number : 0560001
    Brussels, 1200, Belgium
    Recruiting
  • Universidade Estadual de Campinas (UNICAMP)- Site Number : 0760001
    Campinas, São Paulo 13084-225, Brazil
    Recruiting
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760003
    Ribeirão Preto, São Paulo 14049-900, Brazil
    Recruiting
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760004
    São Paulo, 05403-000, Brazil
    Recruiting
  • Investigational Site Number : 1240001
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
  • Investigational Site Number : 1240005
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
  • Investigational Site Number : 1240003
    Montreal, Quebec H3T 1C5, Canada
    Recruiting
  • Investigational Site Number : 1560001
    Beijing, 100045, China
    Recruiting
  • Investigational Site Number : 1560002
    Wuhan, 430030, China
    Recruiting
  • Investigational Site Number : 3560004
    Bengaluru, 560034, India
    Recruiting
  • Investigational Site Number : 3560002
    Mumbai, 400022, India
    Recruiting
  • Investigational Site Number : 3560001
    Pune, 411004, India
    Recruiting
  • Investigational Site Number : 3560003
    Vellore, 632004, India
    Recruiting
  • Investigational Site Number : 3800002
    Florence, Firenze 50134, Italy
    Recruiting
  • Investigational Site Number : 3800001
    Milan, Milano 20122, Italy
    Recruiting
  • Investigational Site Number : 3800003
    Rozzano, Milano 20089, Italy
    Recruiting
  • Investigational Site Number : 6160003
    Poznan, Greater Poland Voivodeship 60-572, Poland
    Recruiting
  • Klinika Transplantacji Szpiku, Onkologii i Hematologii Dziecięcej - Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu-Site Number: 6160002
    Wroclaw, Lower Silesian Voivodeship 50-556, Poland
    Recruiting
    • Marta Hetman · Contactmartha.hetman@gmail.com · +48 530060737
    • Elzbieta Latos-Grazynska · Principal investigator
  • Investigational Site Number : 6160001
    Warsaw, Masovian Voivodeship 02-091, Poland
    Recruiting
  • Investigational Site Number : 6820002
    Dammam, 34212, Saudi Arabia
    Recruiting
  • Investigational Site Number : 6820001
    Riyadh, 12746, Saudi Arabia
    Recruiting
  • Investigational Site Number : 7240003
    Zaragoza, Aragon 50009, Spain
    Recruiting
  • Investigational Site Number : 7240001
    Esplugues de Llobregat, Barcelona [Barcelona] 08950, Spain
    Recruiting
  • Investigational Site Number : 7240002
    Madrid, Madrid, Comunidad de 28046, Spain
    Recruiting
  • The division of Hematology, National Taiwan University Hospital-Site Number : 1580001
    Taipei City, Taipei 100, Taiwan
    Recruiting
  • Department of pediatrics, Chung Shan University Hospital-Site Number : 1580002
    Taichung, 40201, Taiwan
    Recruiting
  • Investigational Site Number : 7920001
    Istanbul, 34093, Turkey (Türkiye)
    Recruiting
  • Investigational Site Number : 7920002
    Izmir, 35100, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2029, 43 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 43 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 16, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Aug 4, 2029
CompletionEst.
Dec 30, 2031
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added, 6 sites removed; no longer in Romania
Show 13 added (5 United States, 2 Poland, 2 Spain, 1 Brazil, 1 Canada, 1 China, 1 Saudi Arabia)
  • Children's Hospital Los Angeles- Site Number : 8400002 · Los Angeles, United States
  • UCLA Medical Center - Harbor- Site Number : 8400011 · Torrance, United States
  • University of Miami Hospital- Site Number : 8400005 · Miami, United States
  • Tulane University School of Medicine- Site Number : 8400026 · New Orleans, United States
  • University of Michigan Health System - Ann Arbor- Site Number : 8400003 · Ann Arbor, United States
  • Universidade Estadual de Campinas (UNICAMP)- Site Number : 0760001 · Campinas, Brazil
  • Investigational Site Number : 1240005 · Toronto, Canada
  • Investigational Site Number : 1560002 · Wuhan, China
  • Investigational Site Number : 6160003 · Poznan, Poland
  • Investigational Site Number : 6160001 · Warsaw, Poland
  • Investigational Site Number : 6820002 · Dammam, Saudi Arabia
  • Investigational Site Number : 7240003 · Zaragoza, Spain
  • Investigational Site Number : 7240002 · Madrid, Spain
Show 6 removed
  • Investigational Site Number : 7240002 · Madrid, Spain
  • Investigational Site Number : 7240003 · Zaragoza, Spain
  • University of Miami Hospital- Site Number : 8400005 · Miami, United States
  • Tulane University School of Medicine- Site Number : 8400026 · New Orleans, United States
  • Spitalul Clinic De Urgenta Pentru Copii Sfanta Maria Iasi, Department: St. Mary Children's Emergency Clinical Hospital-Site Number : 6420001 · Iași, Romania
  • Spitalul Clinic De Urgenta pentru Copii "Louis Turcanu"-Site Number : 6420003 · Timișoara, Romania
across 2 updates, Oct 19, 2026 – Oct 27, 2026
Site contacts
Changed at 8 sites. See the sites
Show 8 sites
  • Investigational Site Number : 0560002 · Brussels, BelgiumContact removed B•••@hubruxelles.be · •••3654Contact removed (no phone or email listed)
  • Investigational Site Number : 0560001 · Brussels, BelgiumContact removed a•••@saintluc.uclouvain.be · •••2337Contact removed (no phone or email listed)
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760003 · Ribeirão Preto, BrazilContact removed •••6480Contact removed (no phone or email listed)
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760004 · São Paulo, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Investigational Site Number : 3800001 · Milan, ItalyContact removed f•••@policlinico.mi.it · •••5414Contact removed (no phone or email listed)
  • Investigational Site Number : 3800003 · Rozzano, ItalyContact removed m•••@hunimed.eu · •••5981Contact removed (no phone or email listed)
  • Investigational Site Number : 7920001 · Istanbul, Turkey (Türkiye)Contact removed •••6057Contact removed (no phone or email listed)
  • Investigational Site Number : 7920002 · Izmir, Turkey (Türkiye)Contact removed •••6722Contact removed (no phone or email listed)
Oct 19, 2026
Show all 2 updates
  1. Oct 27, 2026
    4 sites removed; no longer in Romania
    Show 4 removed
    • University of Miami Hospital- Site Number : 8400005 · Miami, United States
    • Tulane University School of Medicine- Site Number : 8400026 · New Orleans, United States
    • Spitalul Clinic De Urgenta Pentru Copii Sfanta Maria Iasi, Department: St. Mary Children's Emergency Clinical Hospital-Site Number : 6420001 · Iași, Romania
    • Spitalul Clinic De Urgenta pentru Copii "Louis Turcanu"-Site Number : 6420003 · Timișoara, Romania
  2. Oct 19, 2026
    13 sites added, 2 sites removed
    Show 13 added (5 United States, 2 Poland, 2 Spain, 1 Brazil, 1 Canada, 1 China, 1 Saudi Arabia)
    • Children's Hospital Los Angeles- Site Number : 8400002 · Los Angeles, United States
    • UCLA Medical Center - Harbor- Site Number : 8400011 · Torrance, United States
    • University of Miami Hospital- Site Number : 8400005 · Miami, United States
    • Tulane University School of Medicine- Site Number : 8400026 · New Orleans, United States
    • University of Michigan Health System - Ann Arbor- Site Number : 8400003 · Ann Arbor, United States
    • Universidade Estadual de Campinas (UNICAMP)- Site Number : 0760001 · Campinas, Brazil
    • Investigational Site Number : 1240005 · Toronto, Canada
    • Investigational Site Number : 1560002 · Wuhan, China
    • Investigational Site Number : 6160003 · Poznan, Poland
    • Investigational Site Number : 6160001 · Warsaw, Poland
    • Investigational Site Number : 6820002 · Dammam, Saudi Arabia
    • Investigational Site Number : 7240003 · Zaragoza, Spain
    • Investigational Site Number : 7240002 · Madrid, Spain
    Show 2 removed
    • Investigational Site Number : 7240002 · Madrid, Spain
    • Investigational Site Number : 7240003 · Zaragoza, Spain
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • Investigational Site Number : 0560002 · Brussels, BelgiumContact removed B•••@hubruxelles.be · •••3654Contact removed (no phone or email listed)
    • Investigational Site Number : 0560001 · Brussels, BelgiumContact removed a•••@saintluc.uclouvain.be · •••2337Contact removed (no phone or email listed)
    • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760003 · Ribeirão Preto, BrazilContact removed •••6480Contact removed (no phone or email listed)
    • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760004 · São Paulo, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Investigational Site Number : 3800001 · Milan, ItalyContact removed f•••@policlinico.mi.it · •••5414Contact removed (no phone or email listed)
    • Investigational Site Number : 3800003 · Rozzano, ItalyContact removed m•••@hunimed.eu · •••5981Contact removed (no phone or email listed)
    • Investigational Site Number : 7920001 · Istanbul, Turkey (Türkiye)Contact removed •••6057Contact removed (no phone or email listed)
    • Investigational Site Number : 7920002 · Izmir, Turkey (Türkiye)Contact removed •••6722Contact removed (no phone or email listed)
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07285460
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Dec 18, 2025
Primary completion
Aug 4, 2029 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Oct 27, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fitusiran

Start the discussion